Researchers from Genethon, the AFM-Téléthon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a “shortened” version of the dystrophin gene) via a drug vector, the researchers managed to restore muscle strength and stabilise the clinical symptoms in dogs naturally affected by Duchenne muscular dystrophy.
This work published in Nature Communications has been achieved thanks to the donations of the French Téléthon.
Teams at Genethon developed, in collaboration with a team at Royal Holloway University of London led by Pr. Dickson, and produced, a gene therapy drug combining an AAV-type viral vector with a shortened version of the dystrophin gene (approximately 4,000 base pairs), allowing the production of a functional protein. Dr Le Guiner’s team tested this innovative treatment in 12 dogs naturally affected by Duchenne muscular dystrophy. By injecting this microdystrophin intravenously, and hence into the whole body of the dogs, the researchers observed that dystrophin expression returned to a high level, and muscle function was significantly restored, with stabilisation of the clinical symptoms observed for over 2 years following injection of the drug. No immunosuppressive treatment was administered beforehand, and no sideeffects were observed.
Some Golden Retrievers develop Duchenne muscular dystrophy naturally. The successful treatment of these dogs, which show the same clinical symptoms as children with this disease, and are of a similar weight, is a decisive step toward developing the same treatment in children. “This preclinical study demonstrates the safety and efficacy of microdystrophin, and makes it possible to consider developing a clinical trial in patients. Indeed, this is the first time that it has been possible to treat the whole body of a large sized animal with this protein. Moreover, this innovative approach allows treatment of all patients with Duchenne muscular dystrophy, regardless of the genetic mutation responsible,” says Caroline Le Guiner, the main author of this study.
Learn more: Gene therapy: Microdystrophin restores muscle strength in Duchenne muscular dystrophy
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Curi Bio Launches MantaReady™ iPSC-Derived Skeletal Muscle Myoblastson June 6, 2023 at 6:00 am
Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReady TM iPSC-Derived Skeletal Muscle Myoblasts specifically ...
- FibroGen: Several Pamrevlumab Data Releases Could Change Scope Of Biotechon June 5, 2023 at 12:27 pm
FibroGen has two major data readouts approaching, which deal with the use of pamrevlumab. Click here to read why FGEN stock is a Strong Buy.
- MDA Muscle Walk is Powerful Show of Strength and Hopeon June 4, 2023 at 4:14 am
The event, organized by the Muscular Dystrophy Association, aimed to raise funds and awareness to support those affected by neuromuscular diseases.
- ‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work?on June 2, 2023 at 9:55 am
The FDA’s decision, expected this month, follows several setbacks and delays and will pose difficult choices for the families of children with Duchenne muscular dystrophy.
- Researchers link death in gene-editing study to a virus used to deliver the treatment, not CRISPRon May 31, 2023 at 2:50 pm
The lone volunteer in a gene-editing study targeting a rare form of Duchenne muscular dystrophy most likely died after having a reaction to the virus that delivered the therapy in his body ...
- Decision date for Sarepta’s Duchenne muscular dystrophy gene therapy delayed by FDAon May 30, 2023 at 10:18 pm
Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) had delayed its accelerated approval decision on the company’s Duchenne muscular dystrophy (DMD) investigational gene ...
- What Is Muscular Dystrophy (MD)?on May 28, 2023 at 5:41 pm
JohnnyGreig / Getty Images Muscular dystrophy leads to worsening muscle weakness over time. While there are nine different types of MD, the two main types are: Duchenne muscular dystrophy ...
- Protein can improve muscle function in Duchenne muscular dystrophy: Studyon May 25, 2023 at 4:15 am
DMD, caused by mutations in the dystrophin gene, is an inheritable neuromuscular disorder that occurs in one out of 3,600 male births. DMD patients undergo severe muscle wasting, inability to walk, ...
- Discovery slows down muscular dystrophyon May 24, 2023 at 5:48 pm
Jan. 31, 2019 — Researchers have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease. The team restored muscle stem ...
- Discovery Slows Down Muscular Dystrophyon May 24, 2023 at 9:01 am
A team of researchers at the University of Houston College of Pharmacy is reporting that by manipulating TAK1, a signaling protein that plays an important role in development of the immune system, ...
via Google News and Bing News